ACE-031 1mg Human Growth Peptides Hormones ACVR2B To inhibit myostatin

ACE-031, also referred to as ACVR2B or ActRIIB-IgG1, is a synthetically produced protein that was originally developed by two bio-pharmaceutical companies, namely Acceleron and Shire, for its potential ability to inhibit myostatin and other naturally occurring proteins that limit muscle growth.

It was hypothesized that ACE-031 would act as a decoy receptor for the catabolic proteins, specifically myostatin, and bind to them in an effort to keep them away from muscle fibers. Numerous studies have been conducted to determine if ACE-031 is an effective treatment for children who have Duchenne Muscular Dystrophy (DMD).

ACE-031 1mg Human Growth Hormones Peptides ACVR2B To inhibit myostatin

ACE-031 Quick View:

ACVR2B (ACE-031) has to be the coolest and strangest thing out there. It is a monoclonal antibody genetically engineered to bind to myostatin before myostatin can bind to its receptor and stop muscle growth.

What is Myostatin and Why Stop It?

Myostatin, abbreviated GDF-8 (Growth Differentiation Factor-8), is a protein naturally produced in mammals, which acts on muscle cells as an inhibitor of myogenesis (differentiation and growth of muscle cells). The gene encoding myostatin was discovered in 1997 by geneticists Se-Jin Lee and Alexandra McPherron who produced a strain of mutant mice that lack the gene. These scientists produced a strain of mice that lacked the gene and had approximately twice as much muscle as normal mice.

Simple simple simple version: Myostatin tells muscle cells to not grow and not to replicate. Blocking myostatin will help muscles get bigger, to date there has been only Follistatin that is widely used to block myostatin.

ACE-031 Applications:

ACE-031 acts by binding to proteins that normally signal through a particular activin receptor called ActRIIB. Myostatin and other related proteins signal through this receptor to limit muscle growth. When ACE-031 binds to these proteins, it prevents them from interacting with the ActRIIB receptor, thus allowing muscle to grow.

The critical difference between ACE-031 and antibodies to myostatin is that ACE-031 inhibits multiple regulators of muscle mass in addition to myostatin. In preclinical studies, the end result is a greater increase in muscle mass than can be achieved by blocking myostatin alone. In Duchenne, the goal is to offset the loss of muscle due to the lack of dystrophin by increasing the production of new muscle.

Related products:

Our Advantages: